fda warning semaglutide The sent a letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know The obesity drug semaglutide (Wegovy)

Biomarkers and genetic predispositions can help contextualize how individuals may respond to peptide therapies

Potential Side Effects and Considerations Like other GLP-1s, the most commonly observed side effects were digestive, including nausea, diarrhoea, vomiting, and constipation

Ozempic | European Medicines Agency (EMA)

The request from the Department of Administration would require state workers to enroll in an "enhanced weight management program" run by CVS Health in order to have their insurance share the cost

Given the heterogeneity of AUD and the complexity of the effect of alcohol on neural and physiological systems, there is a critical need to explore alternative pharmacotherapies that act through novel mechanisms